SpyGlass Pharma(SGP)
$34.97+0.79 (+2.31%)
SGP
SpyGlass Pharma financials statements
$34.97
At close:+0.79 (+2.31%)
SpyGlass Pharma (SGP) Ratios
33 Followers
SpyGlass Pharma Ratios
SGP's free cash flow for Q2 2026 was $-16.77M. For the 2026 fiscal year, SGP's free cash flow was decreased by $-1.93M and operating cash flow was $-14.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 12.67 |
| Quick Ratio | 12.67 |
| Cash Ratio | 11.23 |
| Solvency Ratio | -0.18 |
| Operating Cash Flow Ratio | -3.81 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -105.94M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.01 |
| Debt-to-Equity Ratio | -0.02 |
| Debt-to-Capital Ratio | -0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -1.17 |
| Debt Service Coverage Ratio | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.05 |
| Net Debt to EBITDA | 2.41 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 96.19% |
| Return on Assets (ROA) | -34.41% |
| Return on Equity (ROE) | 40.34% |
| Return on Capital Employed (ROCE) | -38.64% |
| Return on Invested Capital (ROIC) | -38.64% |
| Return on Tangible Assets | -34.41% |
| Earnings Yield | -4.73% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.23 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | -1607.91 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 1607.91 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -1.02 |
| Free Cash Flow Per Share | -1.05 |
| Dividend Paid and CapEx Coverage Ratio | -41.45 |
| Capital Expenditure Coverage Ratio | -41.45 |
| Operating Cash Flow Coverage Ratio | -20.67 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -3.98% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -21.12 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -8.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -25.16 |
| Price-to-Operating Cash Flow Ratio | -25.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -19.05 |
| Enterprise Value | 747.68M |
| EV to EBITDA | -19.05 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -22.33 |
| EV to Operating Cash Flow | -22.86 |
| Tangible Book Value Per Share | -3.10 |
| Shareholders’ Equity Per Share | -3.10 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -1.25 |
| Tax Burden | 1.00 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.82 |
Currency in USD
